Welcome to our dedicated page for Orbsat news (Ticker: NXPLW), a resource for investors and traders seeking the latest updates and insights on Orbsat stock.
NextPlat Corp (NASDAQ: NXPL, NXPLW) is frequently in the news as a global consumer products and services company that reports on developments across healthcare, communications and e-commerce. Its press releases cover topics such as new healthcare contracts, progress in satellite-enabled connectivity and IoT, and the launch of consumer health brands and AI-powered software.
Investors and followers of NXPLW news can expect updates on healthcare services delivered through PharmcoRx and Progressive Care, including 340B prescription volumes, multi-state prescription fulfillment agreements and new clinic relationships. The company also issues news on its ClearMetrx healthcare data analytics platform, including the development of ClearMetrx 4.0 with AI-enhanced capabilities for revenue forecasting, inventory management, anomaly detection and fraud analytics.
In the communications segment, NextPlat’s news often highlights satellite-enabled connectivity and IoT offerings from its Global Telesat Communications subsidiary and related distribution agreements. Recent announcements include an agreement with Telit Cinterion that adds advanced 5G connectivity to GTC’s existing satellite and terrestrial suite, targeting industrial and enterprise IoT markets in more than 150 countries.
NextPlat also reports on its e-commerce development program, including the launch of its Florida Sunshine brand of premium vitamins and supplements in the United States, the UK and Europe, and preparations for sales in China through Tmall Global. Corporate governance, leadership changes, cost-reduction measures and Nasdaq listing updates are additional recurring themes in NXPLW news. This page aggregates these company-issued updates so readers can follow how NextPlat describes the evolution of its healthcare, communications and e-commerce activities over time.
NextPlat (NASDAQ: NXPL) announced a 1-for-10 reverse stock split effective at 12:01 AM ET on April 13, 2026. Every ten pre-split shares will be consolidated into one post-split share, reducing outstanding shares from approximately 26.9 million to approximately 2.7 million.
The company's common stock will open for trading on The Nasdaq Global Market on April 13, 2026 on a post-split basis under the existing ticker NXPL and a new CUSIP 68557F 308. Fractional shares will be settled for cash in lieu; authorized shares remain at 50 million and par value stays at $0.0001.
NextPlat (NASDAQ: NXPL) reported consolidated revenue of $54.3 million for 2025, down 18% year-over-year, driven by lower prescription volume. Healthcare revenue was $39.7 million and e-commerce revenue was $14.6 million. Gross margin declined to ~20% from 26% in 2024.
Operating expenses fell ~50% to $19.9 million; net loss attributable to common stockholders was $11.7 million or ($0.44) per diluted share. The company ended 2025 with ~$13.7 million cash, no meaningful unsecured debt, and ~$15.0 million working capital, and said cost-cutting and 340B/fulfillment focus will support 2026 profitability.
NextPlat (NASDAQ: NXPL) announced a 1-for-10 reverse stock split effective 12:01 a.m. ET on April 6, 2026, with split-adjusted trading to begin on Nasdaq on April 7, 2026 under the existing ticker NXPL.
The split will reduce outstanding shares from 27,026,215 to approximately 2,702,621, cashed-out fractional shares, will not reduce authorized shares, and aims to regain compliance with Nasdaq's minimum bid price requirement.
NextPlat (NASDAQ: NXPL) announced a collaboration with HealthWarehouse to enable nationwide prescription and OTC fulfillment to all 50 U.S. states, expanding PharmcoRx beyond Florida.
The agreement leverages HealthWarehouse's NABP‑accredited digital pharmacy and national fulfillment to support rapid e-commerce expansion and revenue growth in 2026.
NextPlat (NASDAQ: NXPL) will release full-year 2025 financial results on Tuesday, March 31, 2026. Management will host a conference call at 8:30 a.m. Eastern to discuss results and recent developments.
Investors must submit Q&A questions by March 27, 2026 to investors@nextplat.com. The live webcast and replay will be available via the company webcast link and the investor relations site; phone dial-in and replay numbers are provided.
NextPlat (NASDAQ: NXPL) announced that its Global Telesat Communications subsidiary was awarded a two-year contract worth up to $820,000 from a U.K. government prime supplier to supply satellite-enabled IoT hardware in support of a NATO military end user.
The program uses Iridium Certus dual-mode satellite and LTE terminals for voice, data, and asset management to enable resilient, global connectivity.
NextPlat (NASDAQ: NXPL) expanded Orbital Satcom into South America by launching online storefronts on Mercado Libre in Mexico, Brazil, Argentina, Chile and Colombia.
The sites offer satellite and wireless connectivity products using Globalstar, Iridium and Inmarsat, target millions of customers, and plan further country rollouts in Q2 2026.
NextPlat (NASDAQ: NXPL) expects approximately $55 million in 2025 revenue and reports sequential Q4 2025 improvement versus Q3 driven by higher-margin 340B and contracted services.
Key metrics: 340B revenue +90% QoQ, prescription volume +7% sequentially, anticipated Q1 2026 consolidated gross margin of 20%-25%, cash ~$13M, working capital ~$15M, and zero unsecured debt. Results are preliminary and subject to audit; Form 10-K expected by March 31, 2026.
NextPlat (NASDAQ: NXPL) announced that its Global Telesat Communications (GTC) subsidiary signed a distribution agreement with Telit Cinterion to add advanced 5G and AI-powered IoT device and connectivity solutions to GTC's satellite and terrestrial portfolio.
The partnership targets industrial and enterprise IoT sectors — manufacturing, agriculture, transport, logistics, energy — and leverages Telit Cinterion's global device management and connectivity infrastructure. The release cites a global IoT market valuation of ~USD 1.18 trillion and a projected CAGR of ~11.4% to 2030.
NextPlat (NASDAQ: NXPL) said expanded business development initiatives in H2 2025 are driving material healthcare revenue gains. The company expects nearly 75% sequential quarterly growth in 340B contract revenue in Q4 2025 versus Q3 2025, supported by a preliminary tally of over 12,000 additional 340B and contracted prescriptions from October–early December 2025.
NextPlat credited two revenue-generating healthcare contracts secured earlier in 2025 and an expanded business development role for Chairman Rodney Barreto. The company is also exploring accretive joint ventures and potential acquisitions to expand pharmacy services in Florida and nationally.